- Investigational compound BI ENaC inhibitor delivered twice daily via the Respimat®, a handheld inhaler
INGELHEIM, Germany -- (BUSINESS WIRE) --
Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CFTM 1 to evaluate a new potential treatment for cystic fibrosis.1,2 The trial will investigate how different doses of the compound, an inhaled epithelial sodium channel (ENaC) inhibitor, impact lung function compared to placebo when added to the standard of care in adults and adolescents with cystic fibrosis.1,3,4
People with cystic fibrosis have genetic mutations that cause mucus in various organs to become thick and sticky.5 In the lungs, thick and sticky mucus clogs the airways and traps germs, like bacteria, leading to infections, inflammation, respiratory failure and other complications.6 The inhaled ENaC inhibitor (BI 1265162) is designed to block the absorption of sodium that may keep the surface of the airways hydrated, which may help make mucus less thick, making it easier to keep airways clear in cystic fibrosis.7,8
The ENaC inhibitor is intended to treat patients with all types of cystic fibrosis mutations.1,9 It is inhaled via the Respimat®1, which is the platform inhaler of Boehringer Ingelheim. The Respimat® inhaler actively delivers medicine in a slow-moving soft mist that is easy to inhale even for people who have difficulty breathing.10,11 People with cystic fibrosis often have a high treatment burden, sometimes spending hours administrating multiple treatments.12 The BI 1265162 ENaC inhibitor is delivered via the Respimat®1 to offer a quick inhalation that can be taken anywhere and is intended to be added to the standard of care.
“We are pleased to enrol our first patient into this Phase II trial, and we hope our ENaC inhibitor will be proven to help people affected by cystic fibrosis,” said Dr Kay Tetzlaff, Head of Medicine, Therapeutic Area Inflammation, Boehringer Ingelheim. “Boehringer Ingelheim is committed to researching new treatments that address serious unmet needs. We are hopeful that this treatment, along with its delivery method, will make an important difference for patients affected by this debilitating condition.”
Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.6 Despite improved treatment options in recent years, patients still face deteriorating health and have a median life expectancy in their 40s.12
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Eaton InfiniTrac Electronic
绘锦绣画卷 ——庆祝中国共产党成立100周年杭
2022年新冠疫情期间出台的灵活法律法规使跨国
CES 2020圆满落幕:人工智能和5G定义创新的未来
顶尖律所ROSEN鼓励Ocugen
NTT实现世界超快速石墨烯光电探测器零偏压运行
神策数据荣获北京市广播电视局优秀推荐项目
杨开刚:天生的画家,未来之巨匠
投资者须知:顶级律师事务所ROSEN鼓励投资Fra
DOCOMO将携手海外合作伙伴进一步扩大5G试验
阳信二中参加中美中小学校长交流暨合作洽谈会
《六尺巷》音乐故事将于11月4日晚19点02分首登
平度市人民法院:电视台对“无讼村庄(社区)
香港桂冠论坛:召集天文学等领域的杰出青年科
焕多多——企业库存压力大,利用“易货”消库
FarEye研究称糟糕的配送体验可能会让零售商失去
Market Access Transforma
Xsolla创始人Shurick Agapitov
Conviva的新数据揭示成功驾驭TikTok算法
One IBC基于高水平的客户满意度打造信任
“金沙用心”时刻守护您的旅行安全
武田以高达2.78亿美元的价格向Celltrion剥离亚
Novasec将为西班牙最大的陆上风电场筹资8,000万欧
湖南省芷江检察院第一党支部开展12月份党日活